Search - tctmd.com

Displaying 281 - 300 of 476

Sort: Relevancy | Date

News Conference News AHA 2017

Reimbursement Remedy Backfires: Stress Tests Have Shifted From Private Practice to Hospitals, Driving Up Costs

Yael L. Maxwell

November 16, 2017

News Conference News AHA 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

Todd Neale

November 15, 2017

Presentation AHA 2017

Insights from the FOURIER Trial

Presenter: Marc P. Bonaca

November 15, 2017

News Conference News AHA 2017

Survey Says: Interventionalists Believe Public Reporting Leads to High-Risk PCI Avoidance, Upcoding

Yael L. Maxwell

November 15, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

Presentation AHA 2017

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Presenter: Andre Lamy

November 15, 2017

News Conference News AHA 2017

Accelerator-2: Streamlined Regional STEMI Care Speeds Up Treatment, Lowers Mortality

Michael O'Riordan

November 14, 2017

News Conference News AHA 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

Shelley Wood

November 14, 2017

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

Presentation AHA 2017

Impact of Regionalization of ST Elevation Myocardial Infarction Care

Presenter: James G. Jollis

November 14, 2017

News Conference News AHA 2017

One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs

Shelley Wood

November 14, 2017

News Conference News AHA 2017

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Caitlin E. Cox

November 14, 2017

Presentation AHA 2017

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Presenter: Mar Pujades-Rodriguez

November 14, 2017

Presentation AHA 2017

The POISE-2 PCI Substudy

Presenter: Michelle M. Graham

November 14, 2017

Presentation AHA 2017

Subgroup Analysis from the RE-DUAL PCI Trial

Presenter: Jonas Oldgren

November 14, 2017

Presentation AHA 2017

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Presenter: Kenneth W. Mahaffey

November 14, 2017

Presentation AHA 2017

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Presenter: Louise Bowman

November 14, 2017

News Conference News AHA 2017

Long-Awaited Hypertension Guidelines Released at AHA

Todd Neale

November 13, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

Advertisement

Reimbursement Remedy Backfires: Stress Tests Have Shifted From Private Practice to Hospitals, Driving Up Costs

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

Insights from the FOURIER Trial

Survey Says: Interventionalists Believe Public Reporting Leads to High-Risk PCI Avoidance, Upcoding

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Cost Impact of Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial

Accelerator-2: Streamlined Regional STEMI Care Speeds Up Treatment, Lowers Mortality

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Impact of Regionalization of ST Elevation Myocardial Infarction Care

One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

The POISE-2 PCI Substudy

Subgroup Analysis from the RE-DUAL PCI Trial

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Long-Awaited Hypertension Guidelines Released at AHA

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content